---
title: "300642.SZ (300642.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300642.SZ/news.md"
symbol: "300642.SZ"
name: "300642.SZ"
parent: "https://longbridge.com/en/quote/300642.SZ.md"
datetime: "2026-05-21T01:42:58.890Z"
locales:
  - [en](https://longbridge.com/en/quote/300642.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300642.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300642.SZ/news.md)
---

# 300642.SZ (300642.SZ) — Related News

### [Tellgen: Subsidiary obtains patent for "Application of Combined Detection in the Diagnosis of Malignant Pleural Mesothelioma"](https://longbridge.com/en/news/286750026.md)
*2026-05-18T09:55:53.000Z*
> Tellgen's subsidiary, Jia Yu Life, has obtained an invention patent issued by the National Intellectual Property Adminis

### [Tellgen: Plans to acquire 6.7842% equity of Kanglu Bio for 27.137 million yuan](https://longbridge.com/en/news/284008919.md)
*2026-04-24T13:09:54.000Z*
> Tellgen announced that the company plans to acquire 737,800 shares of Kanglu Bio held by shareholders Chen Gang and Xie 

### [Zhitong A-share lock-up release overview | March 20](https://longbridge.com/en/news/279866160.md)
*2026-03-20T01:01:03.000Z*
> On March 20th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approxim

### [Tellgen's subsidiary obtained 2 medical device registration certificates](https://longbridge.com/en/news/277938168.md)
*2026-03-05T12:49:02.000Z*
> Tellgen's subsidiary, Jiangxi Tellgen Life Science Technology Co., Ltd., recently obtained two medical device registrati

### [Tellgen: Expected net profit in 2025 to decrease by 83.90%-89.23% year-on-year](https://longbridge.com/en/news/274121766.md)
*2026-01-29T09:05:06.000Z*
> Tellgen announced that it expects a net profit of RMB 3.72 million to RMB 5.56 million for the fiscal year 2025, a year-

### [Tellgen: Wholly-owned subsidiary obtains 1 medical device registration certificate](https://longbridge.com/en/news/273084138.md)
*2026-01-20T12:33:14.000Z*
> Tellgen's wholly-owned subsidiary, Shanghai Tellgen Diagnostic Technology Co., Ltd., recently obtained a medical device 

### [Tellgen: Medical device registration for the detection kit of chromosomal and genetic abnormalities in myelodysplastic syndromes (fluorescence in situ hybridization method) has been accepted](https://longbridge.com/en/news/272240690.md)
*2026-01-12T08:50:06.000Z*
> The registration application for the "Chromosomal and Genetic Abnormality Detection Kit for Myelodysplastic Syndromes (F

### [Tellgen: Obtained the invention patent certificate for the application of hybridoma cell line 1C2B8-2 and its secreted antibodies](https://longbridge.com/en/news/270584422.md)
*2025-12-23T07:44:12.000Z*
> Tellgen announced that the company and its wholly-owned subsidiary recently received an invention patent certificate iss

### [Tellgen's subsidiary has obtained the medical device registration certificate](https://longbridge.com/en/news/270292452.md)
*2025-12-19T10:47:10.000Z*
> Tellgen announced that its wholly-owned subsidiary, Shanghai Tellgen Diagnostic Technology Co., Ltd., recently obtained 

### [Tellgen's subsidiary has obtained a medical device registration certificate](https://longbridge.com/en/news/269698141.md)
*2025-12-15T09:48:02.000Z*
> Tellgen announced that its holding subsidiary Wuhan Kanglu Biotechnology Co., Ltd. has obtained the medical device regis